Costs and benefits of diagnostic testing: four ways to improve patient care by purposive use of in vitro diagnostics
Scientific advances and innovative targeted drugs, especially biologics, have revolutionised the treatment of many diseases. In oncology in particular, previously acute or lethal conditions have come to be considered chronic as new treatments have led to longer life expectancies and a lower rate o...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SMW supporting association (Trägerverein Swiss Medical Weekly SMW)
2017-11-01
|
| Series: | Swiss Medical Weekly |
| Subjects: | |
| Online Access: | https://www.smw.ch/index.php/smw/article/view/2419 |
| _version_ | 1798003654223986688 |
|---|---|
| author | Carmen Binder Maximilian Schmid Thomas Dieterle Hans Hendrik Schäfer |
| author_facet | Carmen Binder Maximilian Schmid Thomas Dieterle Hans Hendrik Schäfer |
| author_sort | Carmen Binder |
| collection | DOAJ |
| description |
Scientific advances and innovative targeted drugs, especially biologics, have revolutionised the treatment of many diseases. In oncology in particular, previously acute or lethal conditions have come to be considered chronic as new treatments have led to longer life expectancies and a lower rate of years lived with disability. These advances, however, come with rising costs in a resource-constrained environment. To achieve cost containment, reimbursement for in-vitro diagnostics (IVDs) is increasingly coming under pressure because they are perceived as a cost factor rather than as a tool to reduce expenditure in the long term. In this conceptual paper, we propose four possible interventions from an industry perspective that may contribute to increase effectiveness of IVD use to counteract increasing healthcare expenditures. These are: (1) fostering prevention, screening, early diagnosis and therapy; promoting (2) comprehensive and (3) stratified disease management; and (4) using targeted treatment alongside companion diagnostics. We conclude that the implementation of policies that promote a fee-for-outcome model rather than fee-for-service reimbursement can support sustainable healthcare.
|
| first_indexed | 2024-04-11T12:11:12Z |
| format | Article |
| id | doaj.art-f2ad05b3d83849f6be48b68a725900a8 |
| institution | Directory Open Access Journal |
| issn | 1424-3997 |
| language | English |
| last_indexed | 2024-04-11T12:11:12Z |
| publishDate | 2017-11-01 |
| publisher | SMW supporting association (Trägerverein Swiss Medical Weekly SMW) |
| record_format | Article |
| series | Swiss Medical Weekly |
| spelling | doaj.art-f2ad05b3d83849f6be48b68a725900a82022-12-22T04:24:36ZengSMW supporting association (Trägerverein Swiss Medical Weekly SMW)Swiss Medical Weekly1424-39972017-11-01147474810.4414/smw.2017.14546Costs and benefits of diagnostic testing: four ways to improve patient care by purposive use of in vitro diagnosticsCarmen Binder0Maximilian Schmid1Thomas Dieterle2Hans Hendrik Schäfer3Institute of Surgical Pathology, University Hospital Zurich, SwitzerlandDepartment of Obstetrics and Feto-maternal Medicine, Medical University of Vienna, Vienna General Hospital, AustriaKantonsspital Baselland, Liestal, SwitzerlandDivisional Medical and Scientific Affairs, F. Hoffmann-La Roche Ltd, Diagnostics Division, Basel, Switzerland; Graduate School of Business, University of Cape Town, South Africa Scientific advances and innovative targeted drugs, especially biologics, have revolutionised the treatment of many diseases. In oncology in particular, previously acute or lethal conditions have come to be considered chronic as new treatments have led to longer life expectancies and a lower rate of years lived with disability. These advances, however, come with rising costs in a resource-constrained environment. To achieve cost containment, reimbursement for in-vitro diagnostics (IVDs) is increasingly coming under pressure because they are perceived as a cost factor rather than as a tool to reduce expenditure in the long term. In this conceptual paper, we propose four possible interventions from an industry perspective that may contribute to increase effectiveness of IVD use to counteract increasing healthcare expenditures. These are: (1) fostering prevention, screening, early diagnosis and therapy; promoting (2) comprehensive and (3) stratified disease management; and (4) using targeted treatment alongside companion diagnostics. We conclude that the implementation of policies that promote a fee-for-outcome model rather than fee-for-service reimbursement can support sustainable healthcare. https://www.smw.ch/index.php/smw/article/view/2419cost containmentearly diagnosishealthcare resource useIVDpersonalised healthcarestratified treatment |
| spellingShingle | Carmen Binder Maximilian Schmid Thomas Dieterle Hans Hendrik Schäfer Costs and benefits of diagnostic testing: four ways to improve patient care by purposive use of in vitro diagnostics Swiss Medical Weekly cost containment early diagnosis healthcare resource use IVD personalised healthcare stratified treatment |
| title | Costs and benefits of diagnostic testing: four ways to improve patient care by purposive use of in vitro diagnostics |
| title_full | Costs and benefits of diagnostic testing: four ways to improve patient care by purposive use of in vitro diagnostics |
| title_fullStr | Costs and benefits of diagnostic testing: four ways to improve patient care by purposive use of in vitro diagnostics |
| title_full_unstemmed | Costs and benefits of diagnostic testing: four ways to improve patient care by purposive use of in vitro diagnostics |
| title_short | Costs and benefits of diagnostic testing: four ways to improve patient care by purposive use of in vitro diagnostics |
| title_sort | costs and benefits of diagnostic testing four ways to improve patient care by purposive use of in vitro diagnostics |
| topic | cost containment early diagnosis healthcare resource use IVD personalised healthcare stratified treatment |
| url | https://www.smw.ch/index.php/smw/article/view/2419 |
| work_keys_str_mv | AT carmenbinder costsandbenefitsofdiagnostictestingfourwaystoimprovepatientcarebypurposiveuseofinvitrodiagnostics AT maximilianschmid costsandbenefitsofdiagnostictestingfourwaystoimprovepatientcarebypurposiveuseofinvitrodiagnostics AT thomasdieterle costsandbenefitsofdiagnostictestingfourwaystoimprovepatientcarebypurposiveuseofinvitrodiagnostics AT hanshendrikschafer costsandbenefitsofdiagnostictestingfourwaystoimprovepatientcarebypurposiveuseofinvitrodiagnostics |